(Q73391432)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10650446%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10650446%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

M J Schwarz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10650446%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M Riedel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10650446%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M Ackenheil

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10650446%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

N Müller

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10650446%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 January 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10650446%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

published in

Biological Psychiatry

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10650446%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10650446%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10650446%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

29-33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10650446%20AND%20SRC:MED&resulttype=core&format=json

Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake.

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Neuroleptic responsivity of negative and positive symptoms in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Adhesion molecules on murine brain microvascular endothelial cells: expression and regulation of ICAM-1 and Lgp 55

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Adhesion to human neurons and astrocytes of monocytes: the role of interaction of CR3 and ICAM-1 and modulation by cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Antibodies to the human 60 kDa heat-shock protein in patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Endothelial cells are the major source of sICAM-1 in rheumatoid synovial tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Inhibition of intercellular adhesion molecule-1 (ICAM-1), soluble ICAM-1 and interleukin-4 by nitric oxide expression in migraine patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Increased numbers of CD5+ B lymphocytes in schizophrenic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Cellular immunity in schizophrenic patients before and during neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Increased frequency of CD8 positive gamma/delta T-lymphocytes (CD8+ gamma/delta+) in unmedicated schizophrenic patients: relation to impairment of the blood-brain barrier and HLA-DPA*02011.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Influence of therapy on antibody-formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Effects of clozapine on plasma cytokine and soluble cytokine receptor levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Increased serum IgE in schizophrenic patients who responded poorly to neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Elevated levels of soluble interleukin 2 receptors in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Hepatitis B vaccination in psychiatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

Immunologic and Coagulation Disorders in Chlorpromazine-Treated Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900206-1

10.1016/S0006-3223(99)00206-1

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10650446%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference